US medical devices company Endologix, which develops minimally invasive treatments for aortic disorders, signed an agreement with medical devices manufacturer Boston Scientific under which the latter becomes the exclusive distributor for its products in China.
The long-term agreement covers distribution rights to Endologix’s EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm Sealing (EVAS) products, and also the right of first negotiation for future product offerings by the medical devices company.
John Onopchenko – Endologix CEO said: “We are excited to partner with Boston Scientific to bring next-generation abdominal aortic aneurysm solutions to patients in China.
“China is one of the largest and fastest-growing EVAR markets in the world, representing an exciting market opportunity for Endologix. We look forward to building our brand in this important market by leveraging the Boston Scientific team’s extensive experience introducing new products for patients suffering from vascular disease.”
Boston Scientific is likely to invest in forming a dedicated sales team to commercialize the Endologix products and drive adoption, as part of the agreement.
On the other hand, Endologix will give commercial and clinical support and training to the Boston Scientific team, with an objective to ensure that the best possible clinical outcomes are achieved. Boston Scientific is likely to commence selling the products following local regulatory approval and subsequent commercial launch of the first product, expected in 2021.
Endologix’s current portfolio includes the Ovation iX Abdominal Stent Graft and the AFX2 Endovascular Abdominal Aortic Aneurysm System. Both the products are minimally invasive solutions designed for repairing aortic aneurysms and had secured US FDA clearance and CE mark.